Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD25 Antibody for GVHD Prevention in EBV-T/NK LPD
NCT07029958Phase 4Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Nov 2024
- Primary completion
- Oct 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of daclizumab in Epstein-Barr virus-associated T-cell and natural killer-cell lymphoproliferative disorders (EBV-T/NK-LPD), sponsored by Beijing Children's Hospital. Started Nov 2024; status: recruiting.
02
Drugs
daclizumab
03
Conditions
Epstein-Barr virus-associated T-cell and natural killer-cell lymphoproliferative disorders (EBV-T/NK-LPD)
Beyond the preview
Go deeper on NCT07029958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07029958.